News

Johnson & Johnson announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in…
Read More...

Pfizer Inc. announced that the Phase 3 CROWN study of LORBRENA (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung…
Read More...

Merck, known as MSD outside the United States and Canada, and Hanmi Pharmaceutical announced that the companies have entered into an exclusive licensing agreement for the development,…
Read More...

GS CORPORATION Japan's leading pharma wholesaler and distributor announced a multi-year strategic business alliance agreement to create an integrated regenerative medicine supply chain…
Read More...

MYR Pharmaceuticals, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D, is pleased to…
Read More...

Catalent announced that it will expand its Argentinian site in Loma Hermosa, Buenos Aires. The expansion, which will add over 11,000 square feet of production space at the facility,…
Read More...

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Seismic Bio, Inc., an…
Read More...

ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics that target respiratory syncytial virus (RSV),…
Read More...

Cellix Bio Pharma completes the acquisition of Avaca Pharma, a formulation development company. Avaca Pharma services include discovery, formulation development, regulatory support, and…
Read More...

G1 Therapeutics, Inc. and Simcere Pharmaceutical Group announced an exclusive license agreement for the development and commercialization of trilaciclib across all indications in…
Read More...

AbCellera announced that LY-CoV555, a human antibody discovered by AbCellera in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research…
Read More...

ImmunityBio, Inc. announced positive preclinical results for its human Ad5 vaccine candidate that contains both the spike (S) and nucleocapsid (N) SARS-CoV-2 proteins (hAd5 S + N) for…
Read More...

Innovent Biologics, Inc. announced that the first patient has been successfully dosed in a Phase 1 clinical trial (CIBI322A101) of the potentially first-in-class recombinant…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600…
Read More...

Pfizer Inc. and BioNTech SE announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to supply 120 million doses of BNT162 mRNA-based vaccine candidate…
Read More...

Sanofi and GSK are in advanced discussions, with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine. The vaccine candidate developed by Sanofi…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600…
Read More...

SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce fully human polyclonal antibodies without the need for human…
Read More...

Teva Pharmaceutical Industries Ltd. who holds (through its Japanese affiliates) with Takeda a joint business venture in the Japanese market, announced a new strategy for its local…
Read More...

Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for its investigational drug pevonedistat for…
Read More...